Aurinia Pharmaceuticals Inc.
AUPHDrugs in Pipeline
6
Phase 3 Programs
3
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
How AUPH's past catalysts played out
0.05% Voclosporin Ophthalmic Solution (VOS)
Dry Eye Syndrome
Voclosporin
Lupus Nephritis
Ciclosporin
Psoriasis
Voclosporin High Dose
Lupus Nephritis
Voclosporin Ophthalmic Solution
Dry Eye
Aritinercept
Myasthenia Gravis, Generalized
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
0.05% Voclosporin Ophthalmic Solution (VOS) | Phase 3 | Dry Eye Syndrome | - | - |
Voclosporin | Phase 3 | Lupus Nephritis | - | - |
Ciclosporin | Phase 3 | Psoriasis | - | - |
Voclosporin High Dose | Phase 2 | Lupus Nephritis | - | - |
Voclosporin Ophthalmic Solution | Phase 2 | Dry Eye | - | - |
Aritinercept | Phase 2 | Myasthenia Gravis, Generalized | - | - |
Lupus Nephritis
3 drugs in this indication
Psoriasis
2 drugs in this indication
Dry Eye Syndrome
1 drug in this indication
Dry Eye
1 drug in this indication
lupus
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Aurinia Pharmaceuticals Inc.'s drug pipeline?→
CatalystAlert tracks 6 drug candidates in Aurinia Pharmaceuticals Inc.'s (AUPH) pipeline across Phase 3, Phase 2. Its lead program is 0.05% Voclosporin Ophthalmic Solution (VOS) (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Aurinia Pharmaceuticals Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Aurinia Pharmaceuticals Inc. (AUPH) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track AUPH biotech catalysts?→
Add AUPH to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Aurinia Pharmaceuticals Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.